Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 23Melanoma 21Carcinoma, Renal Cell 21Neoplasms 8Lung Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Rectal Neoplasms 5Hodgkin Disease 5Adenocarcinoma Of Esophagus 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Nasopharyngeal Carcinoma 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2trastuzumab deruxtecan 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Sigmoidoscopy 1Radionuclide Imaging 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin 1Magnetic Resonance Imaging 1Ipilimumab 1Ibuprofen 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Colonoscopy 1Carboplatin 1Calcium Dobesilate 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Anus Neoplasms × Nivolumab × 30 days × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04444921 2026-05-29

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

National Cancer Institute (NCI)

Phase 3 Active not recruiting
205 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡